For these reasons, the administration of unacylated ghrelin has been proposed as a therapeutic tool for the treatment of obesity-related metabolic and cardiovascular complications [25,26]. This evidence concerns the gene GHRL and obesity due to melanocortin 4 receptor deficiency.